^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Ojemda (tovorafenib) (pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma
Published date:
05/23/2023
Excerpt:
Antitumor activity of tovorafenib in BRAF-mutated melanoma was promising and justifies continued clinical development across multiple settings.
DOI:
10.1007/s00280-023-04544-5
Trial ID:
Source:
Title:
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma
Published date:
05/23/2023
Excerpt:
This first-in-human phase 1 study explored the safety and antitumor activity of tovorafenib….Antitumor activity of tovorafenib in BRAF-mutated melanoma was promising and justifies continued clinical development across multiple settings.
DOI:
10.1007/s00280-023-04544-5
Source:
Title:
PHASE I STUDY OF THE INVESTIGATIONAL, ORAL PAN-RAF KINASE INHIBITOR TAK-580 (MLN2480) IN PATIENTS WITH ADVANCED SOLID TUMORS (ST) OR MELANOMA (MEL): FINAL ANALYSIS
Excerpt:
50% of the 16 BRAF-mut MEL Q2D patients achieved a PR with a median PFS of 4.6 mos (range 1.0–40.8).
DOI:
Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367
Trial ID:
